Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trilaciclib with paclitaxel/carboplatin + tislelizumab in first-line advanced squamous NSCLC
ChiCTR2500115243Phase 2Not yet recruiting
- Sponsor
- Dongguan People's Hospital
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of trilaciclib in Pulmonary squamous cell carcinoma (2 arms), sponsored by Dongguan People's Hospital. Primary endpoint: Objective response rate. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
trilaciclib
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on ChiCTR2500115243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500115243.